Click a keyword to view all the abstracts on this site tagged with that keyword.
- Clinical Response and psoriatic arthritis
- Clinical Response and Rheumatoid Factor
- Clinical Science
- clinical skills
- clinical trials
- Clinical trials and dermatomyositis
- Clinical trials and fibromyalgia
- clinical trials and glucocorticoids
- clinical trials and juvenile idiopathic arthritis (JIA)
- clinical trials and lupus nephritis
- clinical trials and osteoarthritis
- clinical trials and osteoporosis
- clinical trials and outcome measures
- clinical trials and pain
- clinical trials and polymyalgia rheumatica
- clinical trials and psoriasis
- clinical trials and remission
- clinical trials and rheumatic disease
- Clinical trials and rheumatoid arthritis
- clinical trials and rheumatoid arthritis (RA)
- clinical trials and rituximab
- clinical trials and scleroderma
- clinical trials and statistical methods
- clinical trials and systemic lupus erythematosus (SLE)
- clinical trials and systemic sclerosis
- clinical trials and thrombosis
- Clinical trials and tocilizumab
- clinical trials and treatment
- clinical trials and ulcers
- clinical trials and vasculitis
- CMS
- CNS Lupus
- CNS Lupus and autoantibodies
- CNS Lupus and immunoregulation
- CNS Lupus and Immunotherapy
- CNS Lupus and magnetic resonance imaging (MRI)
- CNS Lupus and SLE
- CNS Vasculitis
- CNS Vasculitis and spine involvement
- CNS Vasculitis and treatment
- Co-morbidities
- Co-morbidities and ankylosing spondylitis (AS)
- Co-morbidities and crystal-induced arthritis
- Co-morbidities and psoriatic arthritis
- Co-morbidities and rheumatoid arthritis (RA)
- Co-morbidities and systemic lupus erythematosus (SLE)
- co-stimulation
- co-stimulation and mouse model
- co-stimulation and rheumatoid arthritis (RA)
- co-stimulation and salivary gland
- co-stimulation and therapeutic targeting
- coagulation disorder
- coagulation disorder and juvenile SLE
- coagulation disorder and thrombosis
- cognitive behavioral therapy
- Cognitive dysfunction
- cognitive dysfunction and depression
- Cognitive dysfunction and fibromyalgia
- Cognitive dysfunction and osteoarthritis
- Cognitive dysfunction and rheumatoid arthritis (RA)
- cognitive dysfunction and risk assessment
- cognitive dysfunction and stress
- Cognitive dysfunction and systemic lupus erythematosus (SLE)
- Cognitive dysfunction and uric acid
- Colchicine
- colchicine and familial Mediterranean fever
- colchicine and gout
- Collagen
- collagen and fibroblasts
- collagen and fibrosis
- collagen and histone acetylation
- collagen and human leukocyte antigens (HLA)
- collagen and inflammatory arthritis
- collagen and interleukins (IL)
- collagen and osteoarthritis
- collagen and rheumatoid arthritis (RA)
- collagen and scleroderma
- collagen and systemic sclerosis
- collagen and tolerance
- collagen and treatment
- combination therapies
- combination therapies and remission
- combination therapies and rheumatoid arthritis
- combination therapies and rheumatoid arthritis (RA)
- Communication
- communication and positive affect
- communication and quality of care
- communication and self-management
- Community programs
- community programs and exercise
- community programs and legislation
- Community programs and systemic lupus erythematosus (SLE)
- Comorbidity
- Comorbidity and fibromyalgia
- comorbidity and giant cell arteritis
- Comorbidity and gout
- comorbidity and hypertension
- Comorbidity and juvenile idiopathic arthritis (JIA)
- comorbidity and magnetic resonance imaging (MRI)
- comorbidity and malignancy
- comorbidity and osteoarthritis
- Comorbidity and psoriatic arthritis
- comorbidity and qualitative
- comorbidity and questionnaires
- comorbidity and renal disease
- comorbidity and rheumatic disease
- Comorbidity and rheumatoid arthritis (RA)
- Comorbidity and spondylarthritis
- Comorbidity and spondylarthropathy
- Comorbidity and vasculitis
- Comparative effectiveness and harms
- comparative effectiveness and harms and epidemiologic methods
- comparative effectiveness and harms and juvenile idiopathic arthritis (JIA)
- comparative effectiveness and harms and pediatric rheumatology
- comparative effectiveness and harms and psoriatic arthritis
- comparative effectiveness and harms and rheumatoid arthritis
- comparative effectiveness and harms and rheumatoid arthritis (RA)
- comparative effectiveness and harms and spondylarthritis
- competency
- complement
- complement and complement inhibitors
- complement and cryoglobulinemia
- complement and immunosuppressants
- complement and inflammation
- complement and innate immunity
- complement and interferons
- complement and longitudinal studies
- complement and nephritis
- complement and neutrophils
- complement and polymorphism
- complement and pregnancy
- complement and psoriatic arthritis
- complement and renal disease
- complement and rheumatoid arthritis (RA)
- complement and scleroderma
- complement and systemic lupus erythematosus (SLE)
- complement and thrombosis
- complement and vasculitis
- complement deficiency
- complement deficiency and genetics
- Complement deficiency and juvenile dermatomyositis
- complement deficiency and lupus nephritis
- complement deficiency and systemic lupus erythematosus (SLE)
- complement deficiency and systemic sclerosis
- complement inhibitors
- complement inhibitors and safety
- Complementary alternative medicine
- complementary alternative medicine and patient preferences
- Complementary alternative medicine and systemic lupus erythematosus (SLE)
- complex regional pain syndrome
- Complex regional pain syndrome and disability
- Compliance
- Compliance and DMARDs
- Compliance and gout
- Compliance and methotrexate (MTX)
- Compliance and rheumatoid arthritis (RA)
- complications
- Complications and epidemiologic methods
- complications and genetic architecture
- complications and morbidity and mortality
- complications and musculoskeletal disorders
- complications and rheumatoid arthritis (RA)
- complications and rituximab
- Complications and takayasu arteritis
- complimentary and alternative therapy
- Complimentary and alternative therapy and fibromyalgia
- complimentary and alternative therapy and osteoarthritis
- Complimentary and alternative therapy and rheumatoid arthritis (RA)
- complimentary and diagnosis
- Computed tomography (CT)
- computed tomography (CT) and coronary artery disease
- computed tomography (CT) and cross-sectional studies
- computed tomography (CT) and enthesopathy
- computed tomography (CT) and gout
- computed tomography (CT) and inflammatory bowel disease (IBD)
- computed tomography (CT) and inflammatory myositis
- computed tomography (CT) and interstitial lung disease
- computed tomography (CT) and juvenile idiopathic arthritis (JIA)
- computed tomography (CT) and magnetic resonance imaging (MRI)
- computed tomography (CT) and osteoarthritis
- Computed tomography (CT) and osteoporosis
- computed tomography (CT) and outcome measures
- computed tomography (CT) and rheumatoid arthritis (RA)
- computed tomography (CT) and spine involvement
- computed tomography (CT) and spondylarthritis
- Computed tomography (CT) and vasculitis
- computed tomography (CT) and x-ray
- Confocal Microscopy
- Confounding
- Connective tissue diseases
- connective tissue diseases and diagnosis
- connective tissue diseases and hepatic disorders
- connective tissue diseases and hydroxychloroquine
- connective tissue diseases and interferons
- Connective tissue diseases and interstitial lung disease
- connective tissue diseases and laboratory tests
- connective tissue diseases and nailfold capillaroscopy
- Connective tissue diseases and outcome measures
- connective tissue diseases and prognostic factors
- Connective tissue diseases and pulmonary complications